IL6R and depressive symptom measurement: Of these, we highlight sarilumab and satralizumab as exhibiting the most potential as drug repurposing candidates for depression because they target IL6R, which was identified as the gene exhibiting the strongest potential as a target gene according to the functional annotation scoring system and the validation conducted using the ClinicalTrials.gov and PubMed databases (Table 3).